{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:38:09Z","timestamp":1790026689345,"version":"4.0.1"},"reference-count":61,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Refractory autoimmune mutilineage cytopenias can present in childhood associated with chronic nonmalignant lymphoproliferation (splenomegaly, hepatomegaly, and\/or lymphadenopathy). Cytopenias due to peripheral destruction and sequestration have been well recognized since the 1950s and are often lumped together as eponymous syndromes, such as Evans syndrome and Canale-Smith syndrome. Though their clinical and genetic diagnostic workup may appear daunting, it can provide the basis for early intervention, genetic counseling, and empirical and targeted therapies. Autoimmune lymphoproliferative syndrome (ALPS), activated phosphatidylinositol 3-kinase delta syndrome (APDS), and many other related genetic disorders are otherwise collectively known as inborn errors of immunity (IEI). They present in early childhood as refractory autoimmune cytopenias due to immune dysregulation leading to lymphadenopathy, splenomegaly, and increased susceptibility to lymphoma. More recently, controlled clinical trials have shown that some of these immune system disorders with hematological manifestations might be more readily amenable to specific targeted treatments, thus preventing end-organ damage and associated comorbidities. Over the last 20 years, both rapamycin and mycophenolate mofetil have been successfully used as steroid-sparing long-term measures in ALPS. Current therapeutic options for APDS\/PASLI (phosphoinositide 3-kinase [PI3K]-associated senescent T lymphocytes, lymphadenopathy, and immunodeficiency) include the orally bioavailable PI3K\u03b4 inhibitor, leniolisib, which was licensed by the US Food and Drug Administration (FDA) in 2023 for use in individuals older than 12 years as a targeted treatment. Paradigms learned from patients with rare genetic disorders like ALPS and APDS may help in exploring and streamlining molecular therapy strategies in the wider group of IEIs presenting with refractory cytopenias and lymphoproliferation.<\/jats:p>","DOI":"10.1182\/hematology.2024000537","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:01:36Z","timestamp":1733497296000},"page":"126-136","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":14,"title":["Beyond FAScinating: advances in diagnosis and management of autoimmune lymphoproliferative syndrome and activated PI3 kinase \u03b4 syndrome"],"prefix":"10.1182","volume":"2024","author":[{"given":"V. Koneti","family":"Rao","sequence":"first","affiliation":[{"name":"National Institutes of Health (NIH), Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[{"name":"National Institutes of Health (NIH), Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulbu","family":"Uzel","sequence":"additional","affiliation":[{"name":"National Institutes of Health (NIH), Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"4","key":"2024121115361918800_hem2024000537C1","first-page":"271","article-title":"Diagnosis of the hemolytic anemias","volume":"75","author":"Evans","year":"1951","journal-title":"Calif Med"},{"issue":"1","key":"2024121115361918800_hem2024000537C2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archinte.1951.03810010058005","article-title":"Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology","volume":"87","author":"Evans","year":"1951","journal-title":"AMA Arch Intern Med"},{"issue":"6","key":"2024121115361918800_hem2024000537C3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0022-3476(67)80262-2","article-title":"Chronic lymphadenopathy simulating malignant lymphoma","volume":"70","author":"Canale","year":"1967","journal-title":"J Pediatr"},{"issue":"1","key":"2024121115361918800_hem2024000537C4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10875-017-0456-9","article-title":"Autoimmune cytopenias and associated conditions in CVID: a report from the USIDNET registry","volume":"38","author":"Feuille","year":"2018","journal-title":"J Clin Immunol"},{"issue":"3","key":"2024121115361918800_hem2024000537C5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s10875-020-00769-8","article-title":"Lymphoproliferative disease in CVID: a report of types and frequencies from a US patient registry","volume":"40","author":"Yakaboski","year":"2020","journal-title":"J Clin Immunol"},{"issue":"22","key":"2024121115361918800_hem2024000537C6","doi-asserted-by":"crossref","first-page":"5741","DOI":"10.1182\/blood-2011-07-325217","article-title":"How I treat autoimmune lymphoproliferative syndrome","volume":"118","author":"Rao","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2024121115361918800_hem2024000537C7","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \u201cactivated PI3K\u03b4 syndrome\u201d-targeted therapy with the PI3K\u03b4 inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2024121115361918800_hem2024000537C8","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.2022018546","article-title":"A randomized, placebo-controlled phase 3 trial of the PI3Kdelta inhibitor leniolisib for activated PI3Kdelta syndrome","volume":"141","author":"Rao","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2024121115361918800_hem2024000537C9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaci.2023.11.004","article-title":"Autoimmune lymphoproliferative immunodeficiencies (ALPIDs): a proposed approach to redefining ALPS and other lymphoproliferative immune disorders","volume":"153","author":"Magerus","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"7042","key":"2024121115361918800_hem2024000537C10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nature03723","article-title":"Paths to understanding the genetic basis of autoimmune disease","volume":"435","author":"Rioux","year":"2005","journal-title":"Nature"},{"issue":"2","key":"2024121115361918800_hem2024000537C11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1044-579X(02)00132-3","article-title":"Apoptosis in hematological disorders","volume":"13","author":"Debatin","year":"2003","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2024121115361918800_hem2024000537C12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/10245330500329094","article-title":"Causes and consequences of the autoimmune lymphoproliferative syndrome","volume":"11","author":"Rao","year":"2006","journal-title":"Hematology"},{"issue":"6367","key":"2024121115361918800_hem2024000537C13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/356314a0","article-title":"Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis","volume":"356","author":"Watanabe-Fukunaga","year":"1992","journal-title":"Nature"},{"issue":"4","key":"2024121115361918800_hem2024000537C14","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.4049\/jimmunol.148.4.1274","article-title":"The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen","volume":"148","author":"Watanabe-Fukunaga","year":"1992","journal-title":"J Immunol"},{"issue":"2","key":"2024121115361918800_hem2024000537C15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1172\/JCI115867","article-title":"A novel lymphoproliferative\/ autoimmune syndrome resembling murine LPR\/GLD disease","volume":"90","author":"Sneller","year":"1992","journal-title":"J Clin Invest"},{"issue":"14","key":"2024121115361918800_hem2024000537C16","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1182\/blood-2010-04-280347","article-title":"Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop","volume":"116","author":"Oliveira","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2024121115361918800_hem2024000537C17","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jaci.2009.12.983","article-title":"Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome","volume":"125","author":"Caminha","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"13","key":"2024121115361918800_hem2024000537C18","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood-2008-09-179630","article-title":"FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha\/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function","volume":"113","author":"Magerus-Chatinet","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2024121115361918800_hem2024000537C19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2023.11.006","article-title":"Abnormal biomarkers predict complex FAS or FADD defects missed by exome sequencing","volume":"153","author":"Rensing-Ehl","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2024121115361918800_hem2024000537C20","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0092-8674(95)90013-6","article-title":"Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome","volume":"81","author":"Fisher","year":"1995","journal-title":"Cell"},{"issue":"5215","key":"2024121115361918800_hem2024000537C21","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1126\/science.7539157","article-title":"Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity","volume":"268","author":"Rieux-Laucat","year":"1995","journal-title":"Science"},{"issue":"2","key":"2024121115361918800_hem2024000537C22","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jaci.2012.06.011","article-title":"Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation","volume":"131","author":"Magerus-Chatinet","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2024121115361918800_hem2024000537C23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaci.2023.09.028","article-title":"Combined germline and somatic human FADD mutations cause autoimmune lymphoproliferative syndrome","volume":"153","author":"Pell\u00e9","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2024121115361918800_hem2024000537C24","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jaci.2022.11.028","article-title":"Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations","volume":"151","author":"Maccari","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"2024121115361918800_hem2024000537C25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMoa040036","article-title":"Autoimmune lymphoproliferative syndrome with somatic Fas mutations","volume":"351","author":"Holzelova","year":"2004","journal-title":"N Engl J Med"},{"issue":"25","key":"2024121115361918800_hem2024000537C26","doi-asserted-by":"crossref","first-page":"5164","DOI":"10.1182\/blood-2010-01-263145","article-title":"Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome","volume":"115","author":"Dowdell","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2024121115361918800_hem2024000537C27","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.bj.2021.06.005","article-title":"The genetic landscape of the FAS pathway deficiencies","volume":"44","author":"Magerus","year":"2021","journal-title":"Biomed J"},{"issue":"13","key":"2024121115361918800_hem2024000537C28","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/bloodadvances.2021005835","article-title":"The contribution of rare copy number variants in FAS toward pathogenesis of autoimmune lymphoproliferative syndrome","volume":"6","author":"Jevtich","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2024121115361918800_hem2024000537C29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jacl.2014.09.014","article-title":"Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency","volume":"9","author":"Moraitis","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"6","key":"2024121115361918800_hem2024000537C30","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.clinbiochem.2012.01.016","article-title":"Elevated vitamin B\u2081\u2082 levels in autoimmune lymphoproliferative syndrome attributable to elevated haptocorrin in lymphocytes","volume":"45","author":"Bowen","year":"2012","journal-title":"Clin Biochem"},{"issue":"2","key":"2024121115361918800_hem2024000537C31","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(23)00362-9","article-title":"Diagnostic evaluation of paediatric autoimmune lymphoproliferative immunodeficiencies (ALPID): a prospective cohort study","volume":"11","author":"H\u00e4gele","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"2024121115361918800_hem2024000537C32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1172\/JCI131116","article-title":"Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease","volume":"130","author":"Ravell","year":"2020","journal-title":"J Clin Invest"},{"issue":"5","key":"2024121115361918800_hem2024000537C33","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.07657.x","article-title":"Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies","volume":"145","author":"Teachey","year":"2009","journal-title":"Br J Haematol"},{"issue":"6","key":"2024121115361918800_hem2024000537C34","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2006-01-010124","article-title":"Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)","volume":"108","author":"Teachey","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2024121115361918800_hem2024000537C35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2024121115361918800_hem2024000537C36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood-2015-11-685024","article-title":"Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome","volume":"128","author":"V\u00f6lkl","year":"2016","journal-title":"Blood"},{"issue":"13","key":"2024121115361918800_hem2024000537C37","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2013-10-535393","article-title":"Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations","volume":"123","author":"Price","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2024121115361918800_hem2024000537C38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V98.1.194","article-title":"The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis","volume":"98","author":"Straus","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2024121115361918800_hem2024000537C39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol"},{"issue":"13","key":"2024121115361918800_hem2024000537C40","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1084\/jem.20141759","article-title":"Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K","volume":"211","author":"Lucas","year":"2014","journal-title":"J Exp Med"},{"issue":"6160","key":"2024121115361918800_hem2024000537C41","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage","volume":"342","author":"Angulo","year":"2013","journal-title":"Science"},{"issue":"1","key":"2024121115361918800_hem2024000537C42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s10875-023-01626-0","article-title":"Modulating the PI3K signalling pathway in activated PI3K delta syndrome: a clinical perspective","volume":"44","author":"Berglund","year":"2023","journal-title":"J Clin Immunol"},{"issue":"1","key":"2024121115361918800_hem2024000537C43","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jaip.2023.09.016","article-title":"PI3K\u03b4 pathway dysregulation and unique features of its inhibition by leniolisib in activated PI3K\u03b4 syndrome and beyond","volume":"12","author":"Cant","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"2024121115361918800_hem2024000537C44","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaci.2023.06.015","article-title":"Activated phosphoinositide 3-kinase \u03b4 syndrome: update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity","volume":"152","author":"Maccari","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2024121115361918800_hem2024000537C45","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase \u03b4 syndrome: a large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"2024121115361918800_hem2024000537C46","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1016\/j.jaip.2021.07.044","article-title":"Clinical manifestations and outcomes of activated phosphoinositide 3-kinase \u03b4 syndrome from the USIDNET cohort","volume":"9","author":"Oh","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"18","key":"2024121115361918800_hem2024000537C47","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1182\/blood-2011-04-347641","article-title":"A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation","volume":"118","author":"Neven","year":"2011","journal-title":"Blood"},{"key":"2024121115361918800_hem2024000537C48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3389\/fped.2015.00065","article-title":"Approaches to managing autoimmune cytopenias in novel immunological disorders with genetic underpinnings like autoimmune lymphoproliferative syndrome","volume":"3","author":"Rao","year":"2015","journal-title":"Front Pediatr"},{"issue":"12","key":"2024121115361918800_hem2024000537C49","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/RLU.0000000000002816","article-title":"18F-FDG PET imaging features of patients with autoimmune lymphoproliferative syndrome","volume":"44","author":"Carrasquillo","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"1","key":"2024121115361918800_hem2024000537C50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOP.0b013e32834ea739","article-title":"New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome","volume":"24","author":"Teachey","year":"2012","journal-title":"Curr Opin Pediatr"},{"issue":"7","key":"2024121115361918800_hem2024000537C51","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/pbc.21965","article-title":"Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)","volume":"52","author":"Rao","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2024121115361918800_hem2024000537C52","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1021\/acsmedchemlett.7b00293","article-title":"Discovery of CDZ173 (leniolisib), representing a structurally novel class of PI3K delta-selective inhibitors","volume":"8","author":"Hoegenauer","year":"2017","journal-title":"ACS Med Chem Lett"},{"issue":"10","key":"2024121115361918800_hem2024000537C53","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40265-023-01895-4","article-title":"Leniolisib: first approval","volume":"83","author":"Duggan","year":"2023","journal-title":"Drugs"},{"issue":"12","key":"2024121115361918800_hem2024000537C54","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/bloodadvances.2023011000","article-title":"Long-term treatment with selective PI3K\u03b4 inhibitor leniolisib in adults with activated PI3K\u03b4 syndrome","volume":"8","author":"Rao","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2024121115361918800_hem2024000537C55","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jaci.2023.09.032","article-title":"Interim analysis: open-label extension study of leniolisib for patients with APDS","volume":"153","author":"Rao","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2024121115361918800_hem2024000537C56","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaci.2021.04.036","article-title":"International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome","volume":"149","author":"Dimitrova","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2024121115361918800_hem2024000537C57","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaci.2022.09.002","article-title":"Monogenic early-onset lymphoproliferation and autoimmunity: natural history of STAT3 gain-of-function syndrome","volume":"151","author":"Leiding","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2024121115361918800_hem2024000537C58","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaci.2021.04.039","article-title":"Therapeutic options for CTLA-4 insufficiency","volume":"149","author":"Egg","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2024121115361918800_hem2024000537C59","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood.2022019105","article-title":"PI3king apart a rare disease with targeted therapy","volume":"141","author":"Newman","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2024121115361918800_hem2024000537C60","doi-asserted-by":"crossref","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"10","key":"2024121115361918800_hem2024000537C61","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/126\/2346779\/126rao.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/126\/2346779\/126rao.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T19:51:01Z","timestamp":1733946661000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/126\/526233\/Beyond-FAScinating-advances-in-diagnosis-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000537","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}